



Supplementary Figure 22. Circulating ORF1p levels in breast cancer patients, classified by receptor status, with (A) metastatic and (B) localized disease. First- and second-generation Simoa assays were used to measure circulating ORF1p, with each assay labeled as capture/detector reagent. Blue dashed lines indicate assay limits of detection, accounting for four-fold dilution. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.